Literature DB >> 19958894

Comorbidities in patients with psoriasis.

Alice B Gottlieb1, Frank Dann.   

Abstract

Psoriasis is a common chronic inflammatory disease that is associated with serious comorbidities, including psoriatic arthritis, reduced quality of life, depression, malignancy, and cardiovascular comorbidities. Patients with psoriasis have been shown to have an increased incidence of metabolic syndrome and cardiovascular disease compared with the general population. The chronic inflammatory nature of psoriasis has been suggested to be a contributing and potentially independent risk factor for the development of cardiovascular comorbidities. Understanding the interrelationship between these conditions is important for the management of psoriasis and the associated comorbidities. This review will focus on the range of comorbidities associated with psoriasis, with emphasis on cardiometabolic conditions and the aim of encouraging primary care physicians to screen psoriatic patients for cardiometabolic disorders and risk factors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958894     DOI: 10.1016/j.amjmed.2009.06.021

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  52 in total

1.  Psoriasis: it's more than just the skin.

Authors:  Kenneth R Feingold; Carl Grunfeld
Journal:  J Lipid Res       Date:  2012-06-08       Impact factor: 5.922

2.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

3.  A practical approach to monitoring patients on biological agents for the treatment of psoriasis.

Authors:  Jason J Emer; Amylynne Frankel; Joshua A Zeichner
Journal:  J Clin Aesthet Dermatol       Date:  2010-08

4.  Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab.

Authors:  Jacqueline M Benson; Clifford W Sachs; George Treacy; Honghui Zhou; Charles E Pendley; Carrie M Brodmerkel; Gopi Shankar; Mary A Mascelli
Journal:  Nat Biotechnol       Date:  2011-07       Impact factor: 54.908

5.  Association of Skin Psoriasis and Somatic Comorbidity With the Development of Psychiatric Illness in a Nationwide Swedish Study.

Authors:  Kirk Geale; Martin Henriksson; Jussi Jokinen; Marcus Schmitt-Egenolf
Journal:  JAMA Dermatol       Date:  2020-07-01       Impact factor: 10.282

Review 6.  Managing Mild-to-Moderate Psoriasis in Elderly Patients: Role of Topical Treatments.

Authors:  Joseph G Kamel; Paul S Yamauchi
Journal:  Drugs Aging       Date:  2017-08       Impact factor: 3.923

Review 7.  Managing comorbid disease in patients with psoriatic arthritis.

Authors:  M Elaine Husni; Philip J Mease
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

Review 8.  Psychoneuroimmunology: the example of psoriasis.

Authors:  J Moynihan; E Rieder; F Tausk
Journal:  G Ital Dermatol Venereol       Date:  2010-04       Impact factor: 2.011

9.  Targeting the IL-1 family members in skin inflammation.

Authors:  Liselotte E Jensen
Journal:  Curr Opin Investig Drugs       Date:  2010-11

10.  Depression and the risk of psoriasis in US women.

Authors:  P L Dominguez; J Han; T Li; A Ascherio; A A Qureshi
Journal:  J Eur Acad Dermatol Venereol       Date:  2012-10-03       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.